| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Profusa, Inc. Common Stock$1.06
0 (0%)
F 2Pipeline Score Tools & Services · Clinical
Market Cap
1.18 M
EPS
-283.72
P/E Ratio
-
Value Trade
60.05 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
1.15 M
Operating CF
-2.58 M
Total Assets
862.00 K
Total Liabilities
29.06 M
Equity
-28.20 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
375.00 K
Monthly Burn
859.00 K
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
1.83 M
52 Week Range
0.41 - 957.00
% held by Insiders
0.76 %
% held by Institutions
0.58 %
Enterprise Value
18.27 M
Total Shares
5.35 M
Short %
8.8 %
Float Shares
604.36 K
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Profusa, Inc. Common Stock
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
TBD
▼Reverse Stock SplitCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 4%
Micro Cap (rank 888 of 924)
Percentile RankProfusa, Inc. Common Stock has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Lumee | peripheral artery disease | — | 2026-01-29 | Results from 15 PAD patients with subcutaneous hydrogel sensors implanted in the arm and foot. Tissue oxygenation was measured using both Lumee sensors and tcpO₂. Sensors were monitored over 12 months with visits at days 2, 10, 90, 180, and 365. Read More | Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026 Read More | |
Lumee | peripheral artery disease | — | 2026-01-29 | Results from 15 PAD patients with subcutaneous hydrogel sensors implanted in the arm and foot. Tissue oxygenation was measured using both Lumee sensors and tcpO₂. Sensors were monitored over 12 months with visits at days 2, 10, 90, 180, and 365. Read More | Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026 Read More | |
Lumee | peripheral artery disease | — | 2026-01-29 | Results from 15 PAD patients with subcutaneous hydrogel sensors implanted in the arm and foot. Tissue oxygenation was measured using both Lumee sensors and tcpO₂. Sensors were monitored over 12 months with visits at days 2, 10, 90, 180, and 365. Read More | Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PFSA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PFSA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PFSA
Jul 31, 2026Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
Profusa, Inc. has signed an Option Agreement to acquire G3 Vision Labs, which includes its subsidiaries. The agreement allows Profusa to exercise the option under specific conditions, including financial commitments and approvals. If successful, the acquisition will enhance Profusa's capabilities in the diagnostics sector, leveraging G3's established revenue stream.
Read more →-PFSA
Jul 27, 2026▼ -28.7%on this news· ran to -39% by day 1
Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
Profusa, Inc. has signed a non-binding term sheet to acquire a commercial-stage diagnostics company, which is expected to enhance its operational capabilities and revenue streams. The leadership has undergone significant changes, with Jack Stover appointed as Executive Chairman and CEO. The acquisition, pending due diligence, aims to create a public diagnostics company with national laboratories.
Read more →-PFSA
Jul 2, 2026▼ -23%on this news
Profusa Announces 1-for-25 Reverse Stock Split
Profusa, Inc. has announced a one-for-twenty-five reverse stock split effective July 7, 2026. This action will consolidate approximately 13.2 million shares into about 530 thousand shares, while maintaining the number of authorized shares at 601 million. The move aims to enhance the company's stock value and trading stability.
Read more →-PFSA
Jun 24, 2026▼ -9.7%on this news· ran to -20% by day 3
Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts
Profusa, Inc. announced that shareholders approved all proposals during its 2026 Annual Meeting, including the acquisition of the PanOmics diagnostics platform. The approved measures aim to strengthen the company's balance sheet and ensure compliance with Nasdaq listing requirements. CEO Ben Hwang emphasized the strategic importance of these initiatives for future growth and innovation.
Read more →-PFSA
Jun 12, 2026▼ -17.7%on this news
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
Profusa, Inc. has submitted a response package to GMED as part of the CE Mark review for its Lumee Oxygen Platform. This submission follows successful assessments of the company's quality system and technical documentation. The Lumee platform aims to provide continuous tissue oxygen monitoring, addressing significant clinical needs. However, the review process remains ongoing with uncertain outcomes.
Read more →-PFSA
Jun 10, 2026▼ -9.7%on this newsshared move
Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting
Profusa, Inc. has issued a letter encouraging shareholders to vote in favor of several key proposals at the upcoming Annual Meeting on June 23, 2026. The proposals aim to support the company's Nasdaq listing and facilitate the acquisition of the PanOmics Assay platform. The Board believes these measures are crucial for the company's growth and operational success.
Read more →-PFSA
May 15, 2026Profusa Announces Listing Transfer to The Nasdaq Capital Market
Profusa, Inc. has announced its transfer to The Nasdaq Capital Market effective May 15, 2026. This transition is part of a series of milestones set by the Nasdaq Hearings Panel to ensure compliance with listing requirements. The company focuses on developing tissue-integrated sensors for continuous health monitoring.
Read more →-PFSA
May 8, 2026▲ +5.3%on this news
Profusa Receives Favorable Nasdaq Listing Determination
Profusa, Inc. has received approval from the Nasdaq Hearings Panel to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market. This decision is contingent upon the company's ability to meet specific interim milestones and comply with certain financial requirements by July 6, 2026. Profusa is focused on developing tissue-integrated sensors for continuous biochemical monitoring.
Read more →-PFSA
Apr 6, 2026▲ +144.1%on this news
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
Profusa, Inc. has announced a strategic expansion into molecular diagnostics with a $30 million Letter of Intent to acquire the PanOmics platform from BioInsights LLC. This acquisition aims to enhance Profusa's capabilities in precision diagnostics, particularly for pancreatic cancer applications, and is supported by a partnership with Mayo Clinic. The deal is expected to provide a clear pathway to commercialization and significant growth potential.
Read more →-PFSA
Feb 27, 2026▼ -14.8%on this news
Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
Profusa, Inc. has decided to withdraw its S-1 Registration Statement to pursue a smaller offering that aligns better with its operational needs. The company aims to support the projected revenue from its Lumee Oxygen product and its collaboration with the Mayo Clinic. This decision reflects confidence in their recent operational progress and future market entry plans.
Read more →-PFSA
Feb 13, 2026▼ -33.4%on this news· ran to -44% by day 3
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
Profusa has partnered with Mayo Clinic to advance the commercialization of its Lumee wearable oxygen monitoring technology. This collaboration aims to explore high-impact clinical applications, particularly in areas like cardiovascular and orthopedic health. The initiative seeks to improve patient outcomes through continuous monitoring of tissue oxygen levels, addressing unmet clinical needs.
Read more →-PFSA
Feb 5, 2026▼ -36.4%on this news· ran to -54% by day 3
Profusa Announces 1-for-75 Reverse Stock Split
Profusa, Inc. has announced a 1-for-75 reverse stock split effective February 9, 2026. This consolidation will reduce the number of outstanding shares from approximately 92.4 million to about 1.2 million, while maintaining the par value per share. The move aims to enhance the stock's market perception and streamline trading on Nasdaq.
Read more →-PFSA
Jan 29, 2026Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
Profusa, Inc. presented positive results from a US clinical study on its Lumee oxygen monitoring technology for peripheral artery disease (PAD) patients at the Leipzig Interventional Course 2026. The study demonstrated safety and effectiveness, showing a strong correlation with traditional monitoring methods. The company anticipates significant revenue growth from its European operations starting in Q2 2026.
Read more →-PFSA
Jan 16, 2026Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue
Profusa, Inc. has launched its Lumee tissue oxygen monitoring system for contract research organizations (CROs), aiming to generate immediate revenue. This initiative targets the expanding CRO market, projected to grow significantly by 2034. The system offers real-time biological data, enhancing drug development processes and decision-making for pharmaceutical partners.
Read more →-PFSA
Dec 31, 2025Profusa Bolsters European Commercial Network with New French Distributor, MedSell
Profusa has announced a new distributor partnership with MedSell to commercialize its Lumee Oxygen tissue monitoring device in France. This collaboration aims to enhance patient care for those with Critical Limb Threatening Ischemia (CLTI) and builds upon existing partnerships across Europe. Profusa anticipates significant revenue growth as it expands its market presence, particularly in the European Union.
Read more →-PFSA
Dec 30, 2025▲ +78.3%on this newsshared move
Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35
Profusa, Inc. has restructured its Senior Secured Convertible Notes to enhance repayment flexibility and reduce shareholder dilution. The conversion floor price has been raised to $0.35, and mandatory amortization payments have been eliminated. This restructuring is part of Profusa's efforts to improve its balance sheet and support future growth initiatives.
Read more →-PFSA
Dec 11, 2025Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026
Profusa, Inc. will present clinical data from its US study on Lumee technology at the Leipzig Interventional Course (LINC) 2026. The study focuses on tissue oxygen monitoring in patients with peripheral artery disease. The presentation is scheduled for January 28, 2026, and aims to share insights and engage with healthcare professionals.
Read more →-PFSA
Nov 19, 2025Profusa Announces Third Quarter Business and Financial Highlights Recapitalization reduced net debt to $14 million as of October 31; achieved key milestones to deliver potential 2026 revenue target
Profusa, Inc. announced its third quarter business and financial highlights, noting a significant reduction in net debt from $34 million to $14 million following a successful merger with NorthView Acquisition Corporation. The company achieved key operational milestones and raised $9 million through various financial maneuvers. Profusa aims to deliver substantial revenue in the coming years, targeting $0.5 to $2 million in 2026 and $9 to $13 million in 2027, with a longer-term goal of reaching $200 to $250 million by 2030. Their innovative tissue-integrated sensors are positioned to transform personal and medical health monitoring.
Read more →-PFSA
Oct 30, 2025Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee Oxygen and Glucose Monitoring Launches EU commercialization expected in early 2026; U.S. entry and expanded indications to follo
Profusa has announced its plans to achieve revenue between $200 to $250 million by 2030, primarily through the launch of its Lumee tissue oxygen monitoring system in the European market expected in early 2026. The company is also preparing to enter the U.S. market, with expanded product lines including continuous glucose monitoring anticipated. Profusa's innovative platform is positioned to serve a large addressable market, addressing significant health conditions. However, the firm acknowledges inherent uncertainties affecting its projections as it moves toward commercialization.
Read more →-PFSA
Oct 21, 2025NASDAQ: PFSA October 2025 INVESTOR PRESENTATION "Pioneering real time biochemistry that drives AI - led, personalized healthcare technologies" NASDAQ: PFSA DISCLAIMER AND SAFE HARBOR STATEMENT 2 Disclaimer This presentat
Profusa, Inc. has presented its investment highlights, showcasing its platform technology that supports personalized healthcare solutions through real-time biochemistry. The company anticipates a significant addressable market exceeding $10.5 billion by 2030, particularly in the fields of tissue and pulse oximetry monitoring. With an expected revenue growth from $0.5 million in 2026 to between $200 million and $250 million by 2030, Profusa aims to launch its Lumee tissue oxygen monitoring product in the first half of 2027 in the US and Europe. The presentation emphasizes the integration of AI and machine learning into its healthcare solutions aimed at improving clinical insights.
Read more →-PFSA
Oct 7, 2025Profusa Invests Additional $1 Million in Digital Treasury Assets
Profusa, Inc. has announced an additional $1 million investment in digital treasury assets as part of its strategy to hedge against macroeconomic uncertainties. This investment follows a prior $1 million tranche, totaling $2 million in collaborations with Ascent Partners Fund. The company aims to sustain capital for developing its AI-driven Lumee platform, despite potential risks highlighted in forward-looking statements regarding future performance.
Read more →-PFSA
Aug 15, 2025PROFUSA, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
Profusa, Inc. reported its condensed consolidated balance sheets and statements of operations for the six months ending June 30, 2025. The results reveal a considerable increase in total liabilities alongside a worsening accumulated deficit. Operating expenses have increased slightly, while the company posted a net loss of $5,064 thousand, up from $4,481 thousand during the same period last year. Additionally, cash reserves have significantly decreased, raising concerns about the company's financial health moving forward.
Read more →-PFSA
Aug 11, 2025Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO Board addition served in the Trump Administration, overseei
Profusa, Inc. announces two significant leadership appointments following its business combination with NorthView Acquisition Corp. Former Acting U.S. Secretary of Veterans Affairs Peter O'Rourke has been appointed as Lead Independent Director, while seasoned finance executive Fred Knechtel joins as Chief Financial Officer. Both leaders bring extensive experience that will support Profusa's growth and commercialization of its innovative biosensor technology. Their appointments are seen as pivotal for the company's future directions and operations.
Read more →-PFSA
Aug 6, 2025Profusa, Inc. Provides Strategy Overview and Business Update for Investors
Profusa, Inc. has outlined a strategic growth plan following its recent public listing on Nasdaq. The company aims to drive revenue and expand its technology platform, focusing on continuous monitoring for various biochemical applications. They have established five key pillars to guide their development, including revenue growth and AI infrastructure. Profusa anticipates a significant market opportunity, particularly in tissue oxygen monitoring, with plans to launch in Europe and expand into the U.S. market in the coming years.
Read more →-PFSA
Jul 14, 2025Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday
Profusa, Inc. has announced the successful closing of its business combination with NorthView Acquisition Corp., with its common stock set to begin trading on Nasdaq under the ticker 'PFSA' on July 14, 2025. This marks an important milestone for the company in its mission to enhance chronic disease management and personal health monitoring through innovative biosensor technology. The combined entity will offer a range of products aimed at continuous biochemical monitoring, supported by a recent $9 million convertible note aimed at covering transaction costs and future capital needs.
Read more →-PFSA
Mar 18, 2025ANNEX A PROPOSED AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NORTHVIEW ACQUISITION CORP. Pursuant to Section 242 of the Delaware General Corporation Law NORTHVIEW ACQUISITION CORP. (the "Corpora
NorthView Acquisition Corp. has proposed an amendment to its amended and restated certificate of incorporation under Delaware law. The amendment includes provisions for public stockholders regarding additional redemption rights if the company does not complete a business combination by the specified deadline. The opportunity for redemptions is tied to the approval of any amendments related to stockholder rights. The amendment aims to ensure stockholder interests are preserved, particularly regarding share redemption procedures.
Read more →-PFSA
Dec 26, 2024NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Failure to Complete Initial Business Combination New York, NY
NorthView Acquisition Corporation has received a notice from Nasdaq indicating that its securities will be delisted due to failure to complete its initial business combination within the required timeframe. Trading of the company's common stock, rights, and warrants will be suspended starting December 27, 2024. The company will not appeal this determination and plans to apply for listing on the OTC market. However, the delisting does not affect its ongoing business combination efforts with Profusa Inc.
Read more →-PFSA
Dec 11, 2024NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Quarterly Report on Form 10-Q New York, NY
NorthView Acquisition Corporation has received a notice from Nasdaq regarding its failure to file the quarterly report on Form 10-Q for the period ended September 30, 2024. While this notice does not immediately affect its share listing, the company must comply within 60 days to avoid potential delisting. NorthView is actively working to file the required report within this timeframe, which may prevent the need for a formal compliance plan if accepted by Nasdaq. The company has options to appeal if the plan is not accepted.
Read more →-PFSA
Sep 13, 2024NorthView Acquisition Corporation Announces Exception Granted by Nasdaq to Permit to The Company to Regain Compliance with Listing Rules New York, NY
NorthView Acquisition Corporation received an exception from Nasdaq to comply with its Listing Rule 5250(c)(1), which mandates timely filing of financial reports. The Company must submit its Quarterly Reports for ending periods by October 14, 2024, to avoid delisting. The announcement demonstrates NorthView's commitment to addressing its compliance issues and working diligently to meet the requirements.
Read more →-PFSA
Jun 7, 2024NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Annual Report on Form 10-Q New York, NY
NorthView Acquisition Corporation has received a notice from Nasdaq for failing to file its Form 10-Q by the deadline. While this places the company out of compliance with Nasdaq's listing rules, there is no immediate effect on the listing of its shares. To regain compliance, NorthView has 60 days to plan and potentially file its Form 10-Q, with Nasdaq allowing up to 180 days for compliance if the plan is accepted. The company is working diligently to meet this requirement.
Read more →-PFSA
Nov 7, 2022Profusa, Inc., a Digital Health Company, Pioneering the Next Generation of Personalized Medicine, to Become a Publicly Traded Company Via Merger with NorthView Acquisition Corp New York, New York
Profusa, Inc., a Digital Health Company, Pioneering the Next Generation of Personalized Medicine, to Become a Publicly Traded Company Via Merger with NorthView Acquisition Corp New York, New York, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa"), a digital health co
Read more →-PFSA
Jan 19, 2022NorthView Acquisition Corp. Announces Upcoming Automatic Unit Separation New York, New York
NorthView Acquisition Corp. Announces Upcoming Automatic Unit Separation New York, New York, January 19, 2022 - NorthView Acquisition Corp. (NASDAQ: NVACU) (the "Company") announced today that, on January 21, 2022, the Company's units will no longer trade, and that the Compan
Read more →-PFSA
Dec 22, 2021NORTHVIEW ACQUISITION CORPORATION Index to Financial Statement Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
NORTHVIEW ACQUISITION CORPORATION Index to Financial Statement Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of December 22, 2021 F-3 Notes to F inancial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING To the Stockhold
Read more →-PFSA
Dec 20, 2021NorthView Acquisition Corp. Announces Pricing of Upsized $165,000,000 Initial Public Offering New York, New York
Acquisition Corp. Announces Pricing of Upsized $165,000,000 Initial Public Offering York, New York, Dec. 20, 2021 (GLOBE NEWSWIRE) -- NorthView Acquisition Corp. (NASDAQ: NVACU) (the "Company") announced today that it priced its initial public offering of 16,500,000 units at a
Read more →Competitive Position
How PFSA ranks across every disease it competes inCompetitive Position is a premium feature
See how PFSA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial